Developing a Smoking Cessation Intervention for Methadone Maintained Smokers
The purpose of this study is to pilot and evaluate, in a randomized controlled trial, the immediate and long-term effects of a newly developed, tailored, intensive smoking cessation intervention among methadone maintained smokers and compared to a control condition (facilitated referral to the NJ Quitline). The newly developed intervention is evidence based, addresses the unique needs of methadone maintained smokers, is intensive, can be tailored to the individual, and builds on the strengths as well as addresses the gaps in previous treatments for methadone maintained smokers.
The investigators hypothesize that: (1) three months and six months after beginning treatment, those in the tailored intervention condition will be more likely to be abstinent from smoking than those in the control intervention condition (primary outcome); (2) there will be a greater relapse rate in the control intervention condition between the three and six month follow-up points than in the tailored intervention condition; (3) three and six months after beginning treatment, those in the tailored intervention condition will have better secondary smoking related outcomes (smoked fewer cigarettes per day in the past week, be more ready to quit, have greater self-efficacy for quitting, experience less nicotine dependence, and be more likely to have made a quit attempt) than those in the control intervention condition; (4) three and six months after beginning treatment, those in the tailored intervention condition will have better utilization of and adherence to smoking cessation pharmacotherapy, better mental and physical health, less perceived stress, greater social support, less drug and alcohol use, and greater involvement in drug and alcohol treatment than those in the control intervention condition; and (5) the newly created tailored intervention will be feasible and acceptable. .
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Most individuals in methadone maintenance treatment are tobacco smokers. Also, people in methadone treatment are more likely to experience the health issues related to smoking than the general population. Yet, research has found that smokers receiving methadone treatment are interested in quitting and receiving tobacco cessation treatment, and people in drug treatment who quit smoking are less likely to use drugs.
To better help methadone maintained smokers quit smoking and prevent them from starting smoking again, we want to evaluate the effects of a new smoking cessation counseling intervention, designed for methadone maintained smokers as compared to a smoking cessation counseling intervention used with the general population.
Eligible participants will:
- Be English speaking (i.e., able to participate in counseling sessions in English and to complete study interviews in English);
- Be enrolled in methadone treatment for at least three months;
- Be able to give informed consent;
- Be willing and able to participate in all study activities;
- Not have taken smoking cessation related medication or participated in smoking cessation counseling in the past six months;
- Have smoked at least 100 cigarettes during their lifetime and currently smoke every day or most days;
- Not currently be pregnant or breastfeeding or plan on getting pregnant or breastfeeding during the next six months;
- Have access to a working telephone; and,
- Be interested in participating in a smoking cessation intervention and quitting smoking within the next six months.
Participants will be randomly assigned to receive either a smoking cessation intervention tailored for methadone maintained smokers or a referral to a smoking cessation program available to the general population (NJ Quitline). Participants assigned to receive the tailored intervention, will participate in approximately eight individual counseling sessions, with a smoking cessation counselor, over three months. Each session will last approximately 45 minutes and occur in the participant's methadone clinic. Treatment needs will be assessed during the first session and the intervention will be tailored to participants' needs. Prior to quitting participants will receive nicotine replacement patches and lozenges and instructions on how to use them.
Study staff will contact the NJ Quitline for participants assigned to the control condition, and a counselor from the Quitline will call them.
Regardless of treatment assignment, participants will be asked to provide a urine sample for a drug test and pregnancy test (for women) and complete an interview, using a computer or face-to-face, before beginning treatment or receiving the NJ Quitline referral and three months and six months after study enrollment.Each interview will take approximately 45 minutes to one hour to complete.
Participants will receive a $20 gift card for completing each research visit (i.e., computer or face-to-face interview), but will not be reimbursed for counseling visits.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
New Jersey
-
New Brunswick, New Jersey, Estados Unidos, 08901
- Rutgers Robert Wood Johnson Medical School
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Enrolled in methadone treatment for at least three months
- Able to give informed consent
- Willing and able to participate in all study activities
- Smoked at least 100 cigarettes during their lifetime
- Currently smoke every day or most days
- Has access to a working telephone
- Interested in participating in a smoking cessation intervention and quitting smoking within the next six months
Exclusion Criteria:
- Unable to speak English fluently
- Took smoking cessation related medication or participated in smoking cessation counseling in the past three months
- Pregnant or breastfeeding or planning on becoming pregnant or breastfeeding during the next six months
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Intensive, tailored intervention
Participants in the intensive intervention condition will receive eight individual counseling sessions, with a smoking cessation counselor, over three months.
Each session will last approximately 45 minutes and occur in the methadone clinic.
Participant treatment needs will be assessed during the first session and the intervention will be tailored to the participants' needs.
Prior to quitting participants will receive nicotine replacement patches and lozenges and instructions on how to use them.
|
Eight, 45 minute counseling sessions, tailored to the individual and based on the Information-Motivation-Behavioral Skills model of behavior change.
Incorporates motivational interviewing, education, cognitive-behavioral skills training.
12 week course of nicotine replacement patches provided.
Nicotine lozenges also provided.
Outros nomes:
|
|
Comparador Ativo: Control Intervention
Participants randomized to the control intervention will receive a referral to the NJ Quitline (a telephone smoking cessation counseling service).
Participants will receive a brochure and information about the referral.
Study staff will contact the NJ Quitline for control participants, and a counselor from the Quitline will call control participants.
|
Participants will receive a facilitated referral to the NJ Quitline (i.e.
fax to quit).
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants Who Experienced Seven-day Point Prevalence Smoking Abstinence
Prazo: during the previous seven days at three months post baseline
|
Self-reported not smoking "even a puff" within the previous seven days, and exhaled carbon monoxide reading of <8 parts per million.
|
during the previous seven days at three months post baseline
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Median Number of Cigarettes Participants Smoked Per Day During the Past Week
Prazo: during the previous seven days at three months post baseline
|
Self-reported, median number of cigarettes per day during the previous seven days
|
during the previous seven days at three months post baseline
|
|
Number of Participants Who Experienced Any Quit Attempts Since Baseline
Prazo: During the period between baseline and three months post enrollment
|
Self-reported, smoke free for 24 hours or more since baseline (yes/no)
|
During the period between baseline and three months post enrollment
|
|
Number of Participants Who Experienced Seven-day Point Prevalence of Smoking Abstinence
Prazo: during the previous seven days at six months post baseline
|
Self-reported not smoking "even a puff" within the previous seven days, and exhaled carbon monoxide reading of <8 parts per million.
|
during the previous seven days at six months post baseline
|
|
Median Number of Cigarettes Smoked Per Day During the Past Week
Prazo: during the previous seven days at six months post baseline
|
Self-reported, median number of cigarettes per day during the previous seven days
|
during the previous seven days at six months post baseline
|
|
Number of Participants Who Experienced Any Quit Attempts Since Enrollment
Prazo: during the period between baseline and six months post-enrollment
|
Self-reported, smoke free for 24 hours or more since baseline (yes/no)
|
during the period between baseline and six months post-enrollment
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Nina Cooperman, Psy.D., Rutgers Robert Wood Johnson Medical School
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Transtornos Mentais, Desordem Mental
- Distúrbios induzidos quimicamente
- Transtornos Relacionados a Substâncias
- Transtornos Relacionados a Narcóticos
- Transtorno do Uso de Tabaco
- Distúrbios relacionados a opioides
- Efeitos Fisiológicos das Drogas
- Depressores do Sistema Nervoso Central
- Agentes do Sistema Nervoso Periférico
- Analgésicos
- Agentes do Sistema Sensorial
- Analgésicos, Opioides
- Narcóticos
- Agentes do Sistema Respiratório
- Antitussígenos
- Metadona
Outros números de identificação do estudo
- K23DA025049 (Concessão/Contrato do NIH dos EUA)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .